Bioactive-Tissue-Derived Nanocomposite Hydrogel for Permanent Arterial Embolization and Enhanced Vascular Healing |
| |
Authors: | Jingjie Hu Izzet Altun Zefu Zhang Hassan Albadawi Marcela A Salomao Joseph L Mayer L P Madhubhani P Hemachandra Suliman Rehman Rahmi Oklu |
| |
Affiliation: | 1. Division of Vascular & Interventional Radiology, Minimally Invasive Therapeutics Laboratory, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ, 85259 USA;2. Department of Laboratory Medicine and Pathology, Mayo Clinic, 5777 East Mayo Blvd., Phoenix, AZ, 85054 USA |
| |
Abstract: | Transcatheter embolization is a minimally invasive procedure that uses embolic agents to intentionally block diseased or injured blood vessels for therapeutic purposes. Embolic agents in clinical practice are limited by recanalization, risk of non-target embolization, failure in coagulopathic patients, high cost, and toxicity. Here, a decellularized cardiac extracellular matrix (ECM)-based nanocomposite hydrogel is developed to provide superior mechanical stability, catheter injectability, retrievability, antibacterial properties, and biological activity to prevent recanalization. The embolic efficacy of the shear-thinning ECM-based hydrogel is shown in a porcine survival model of embolization in the iliac artery and the renal artery. The ECM-based hydrogel promotes arterial vessel wall remodeling and a fibroinflammatory response while undergoing significant biodegradation such that only 25% of the embolic material remains at 14 days. With its unprecedented proregenerative, antibacterial properties coupled with favorable mechanical properties, and its superior performance in anticoagulated blood, the ECM-based hydrogel has the potential to be a next-generation biofunctional embolic agent that can successfully treat a wide range of vascular diseases. |
| |
Keywords: | decellularized extracellular matrix embolization hybrid nanocomposite hydrogels transcatheter delivery vascular remodeling |
|
|